Physician profile
Mark Scholz
NPI 1346286093
$61,827.81
in general payments reported to CMS, 2019-2025
41 companies · $2,434 in 2025
The $2,434 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $20K · 2021: $4,617 · 2022: $2,035 · 2023: $2,677 · 2024: $2,636 · 2025: $2,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,539 · Education: $193 · Gift: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,538.58 |
| Education | $193.03 |
| Gift | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20,044.17 | 2019-2025 | |
| Janssen Biotech, INC. | $14,478.63 | 2019-2025 | Erleada, Akeega, Imbruvica |
| Janssen Global Services, LLC | $6,171.39 | 2019-2020 | |
| Astellas Pharma US INC | $4,583.80 | 2019-2024 | Xtandi |
| Dendreon Pharmaceuticals LLC | $4,410.72 | 2019-2025 | Provenge |
| Clovis Oncology, INC. | $2,648.73 | 2020-2021 | |
| Exelixis INC. | $1,802.13 | 2020-2024 | Cabometyx |
| Pfizer INC. | $1,026.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $754.47 | 2021-2025 | Lynparza |
| Amgen INC. | $609.04 | 2019-2023 | Prolia, Xgeva |
| Sumitomo Pharma America, INC. | $495.57 | 2023-2025 | Orgovyx, Gemtesa |
| Sun Pharmaceutical Industries INC. | $452.94 | 2022-2025 | Yonsa |
| Janssen Scientific Affairs, LLC | $429.86 | 2019-2025 | Erleada, Akeega |
| Myriad Genetic Laboratories, INC. | $422.09 | 2020-2025 | Prolaris, Myrisk |
| Novartis Pharmaceuticals Corporation | $416.86 | 2022-2025 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Scholz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.